CD44 and prostate neoplasm: We tested the viability after 24 h of treatment with bare or HA-capped AuNPs of CD44-positive cells (normal endothelial, HUVEC and prostate tumor, PC-3), in comparison with CD44-negative cells (neuroblastoma, SH-SY5Y) (Figure 7).